Testing a targeted antibody for advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that is back (recurrent) or not responding (refractory) or has spread (metastatic), and standard treatment has failed
- You’re 18 or older, and your body strength score (KPS) is at least 60
- Your expected survival time is at least 3 months, based on the study team
- Blood counts, kidney function, liver tests, and clotting tests must be within set safe ranges
- You must be well enough to come to required visits and complete study blood tests and procedures
- If you have glioma (a brain tumor): you must have MRI-supported recurrence and provide tumor tissue for review (or the team may still allow enrollment if you can’t provide it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GNC-077 for people with gastrointestinal or other solid tumors that have spread after standard treatments. Researchers want to see if the drug is safe and can shrink tumors.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This trial tests a new drug called GNC-077 for people with advanced non-small cell lung cancer or other solid tumors that have spread. It aims to see if the drug is safe and helps shrink tumors.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
Hear when a new Recurrent Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.